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Edited by Christian GriesingerAbstract Staurosporine and four staurosporine derivatives were
docked on the rhodopsin-based homology model of the M1 mus-
carinic acetylcholine receptor in order to localize the possible
allosteric sites of this receptor. It was found that there were three
major allosteric sites, two of which are located at the extracellu-
lar face of the receptor, and one in the intracellular domain of the
receptor. In the present study, the localization of these binding
sites is described for the ﬁrst time. The present study conﬁrms
the existence of multiple allosteric sites on the M1 muscarinic
receptor, and lays the ground for further experimental and com-
putational analysis to better understand how muscarinic recep-
tors are modulated via their allosteric sites. These ﬁndings will
also help to design and develop novel drugs acting as allosteric
modulators of the M1 receptor, which can be used in the treat-
ment of the Alzheimers disease.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Muscarinic acetylcholine receptors are members of the
superfamily of G-protein coupling receptors. Within this fam-
ily of receptors, there are ﬁve distinct subtypes falling into two
main groups: The ﬁrst group contains the M1, M3 and M5 sub-
types that preferentially couple to Gq/G11 G-proteins class;
and the second group consists of the M2 and M4 subtypes,
which couple to Gi/Go subclass [1].
Recently, the M1 subtype has received more attention due
to its important role in cognitive processing relevant to the
Alzheimers disease, particularly in short-term memory. It
has been hypothesized that the M1 subtype could be a prom-
ising target for the design and development of drugs that im-
prove cognitive abilities [2]. It was suggested that M1
muscarinic agonists might oﬀer an advantage in treating the
Alzheimers disease, by activating post-synaptic M1 receptors*Corresponding author.
E-mail address: mef@ddt.biochem.umn.edu (L.M. Espinoza-Fonseca).
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doi:10.1016/j.febslet.2005.10.069[2–5]. This strategy is presumably less limited than using
acetylcholinesterase inhibitors, because it does not require
the production and release of acetylcholine from presynaptic
terminals.
However, M1 agonists lack selectivity, which limits their
clinical use. Alternatively, recent studies have shown the pos-
sibility of developing selective M1 allosteric modulators able
to induce a conformational change in the receptor, to in-
crease the aﬃnity of the natural agonist (in this case, acetyl-
choline), and to improve the G-proteins coupling to the
receptor [6,7]. It has also been hypothesized that muscarinic
receptors possess multiple allosteric sites that mediate the ef-
fects of various agents on the binding of ligands to the ace-
tylcholine-binding site [8]. Most of the studied allosteric
agents, such as gallamine, strychnine, brucine, alcuronium,
tubocurarine and others, are consistent with the ternary com-
plex allosteric model, in which the primary and allosteric li-
gands bind simultaneously to the receptor, modifying each
others aﬃnity.
Until now, the location of the allosteric sites of the M1 recep-
tor has been unknown, which has limited the possibility of
understanding the mechanisms in which this type of receptor
is allostericaly modulated. In this study, we performed docking
simulations of staurosporine and four indolocarbazoles (Chart
1) on the rhodopsin-based homology model of the M1 recep-
tor. It has been experimentally shown that these compounds
have a complex allosteric eﬀect on M1–M4 muscarinic recep-
tors, involving more than one allosteric site [9]. In this contri-
bution, we show the existence of three allosteric sites involved
not only in the positive cooperativity with the orthosteric site,
but also in the activation of a possible acetylcholine-indepen-
dent G-protein coupling to the receptor.2. Materials and Methods
2.1. Protein setup
The rhodopsin-based homology model of the M1 muscarinic recep-
tor reported by Hulme and co-workers was employed in present study
ignoring the 129-amino acid deletion in the third intracellular loop (i3).
This deletion did not modify ligand binding activity and shows good
signaling activity [10–12]. The accuracy of the structure and the pro-
tonation states were analyzed with the program WHAT IF [13]. A
disulﬁde bond between residues C98 and C178 was assigned. The
protein was embedded in a TIP3P water box (100 · 80 · 100 A˚). 30blished by Elsevier B.V. All rights reserved.
Chart 1. Chemical structures of the ﬁve allosteric modulators
employed in the present study.
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on the system, and to closely mimic the physiological ionic strength.
Protein and ions were modeled with the CHARMM 27 force ﬁeld.
2.2. Molecular dynamics simulation of the M1 receptor
In order to relax the homology model (e.g., to assign random posi-
tions to the atoms in the model), a short molecular dynamics simu-
lation was performed using the program NAMD 2.6 [14]. For the
simulation, periodic boundary conditions and the particle mesh
Ewald were employed. The non-bonded cutoﬀ, switching distance
and non-bonded pair-list distance were set to 9, 8 and 11 A˚, respec-
tively. The SHAKE algorithm applied to all bonds to hydrogen
atoms allowed a 2-fs time step. NPT ensemble was maintained with
a Langevin thermostat and a Langevin piston barostat. The system
was minimized for 1000 steps using the conjugate gradient algorithm
with restraints to all protein atoms. 1000 Additional steps were used
to minimize the whole system with no restraints. The solvent and
protein were equilibrated, and the whole system was warmed up
and relaxed for 200 ps.
2.3. Ligands setup
Ligands were constructed and optimized using the program MOE
[15]. The optimization was carried out at semi-empirical level using
the AM1 method, and partial charges on atoms were assigned using
the Gasteiger–Marsili method [16]. At the end, the dihedrals allowed
to rotate were assigned with the aid of the program AUTOTORS.
2.4. Docking simulations
Docking simulations were performed with the AutoDock program
(v. 3.0.5) [17]. This program uses the eﬃcient Lamarckian Genetic
algorithm and its scoring function comprised by van der Waals, Cou-lomb potential electrostatics, hydrogen bonding, a volume-based sol-
vation term and an estimation of the entropic cost of binding
through a weighted sum or torsional degrees of freedom terms. Addi-
tionally, one does not need to specify the possible binding site, since
the algorithm allows an eﬃcient searching of the entire surface of
the target.
Grid maps representing the protein were calculated with the aid of
AUTOGRID. A cubic box of 126 · 126 · 126 points, with a spacing
of 0.6 A˚ between the grid points and centered on the geometric center
of the protein, was calculated. The dimensions of the box were big en-
ough to cover the entire surface of the receptor. Docking simulations
were carriedout using theLamarckianGeneticAlgorithm,with an initial
population of 500 individuals, a maximum number of 50000000 energy
evaluations, a maximum number of 27000 generations, a translation
step of 2 A˚, a quartenion step of 50 and a torsion step of 50. For the
local search, the pseudo-Solis and Wets algorithm was applied using a
maximum number of 300 iterations per local search. Docking simula-
tions consisted of 100 independent runs. Resulting orientations lying
within 2.0 A˚ in the RMSD were clustered together and represented by
the orientation with the most favorable free energy of binding.3. Results
Docking simulations of the ﬁve allosteric modulators on
the homology model of theM1 muscarinic receptor revealed the
existence of three principal allosteric binding sites along
the protein surface. Best docking results of each compound
were located in a similar position on the three binding sites.
We labeled these binding sites as follows: (1) EXC (located
close to the entrance of the binding site), (2) ENT (at the
entrance of the binding site), and (3) INC (located in the intra-
cellular domain, close to the intracellular loop). The three
binding sites are shown in Fig. 1. The computed free energies
of binding to each site on the free receptor are summarized in
Table 1. For each allosteric modulator, the results are
described as follows.
3.1. Staurosporine
This molecule constitutes the base structure of the allosteric
modulators studied here. AutoDock placed this molecule on
the three binding sites mentioned above. The best-ranked clus-
ter, containing 31 out of 100 independent runs, docked stauro-
sporine in the INC site. Sixteen independent runs docked this
modulator in the ENT site. Finally, only 5 out of 100 runs
docked it in the EXC allosteric site. The best docking orienta-
tions of staurosporine on the M1 muscarinic receptor are
shown in Fig. 2.
3.1.1. Staurosporine binding to the INC site. The indo-
locarbazol moiety of staurosporine makes contact with resi-
dues S126, A135, T354, F355, S356, V358, K359, E360 and
N422. The rest of the molecule interacts with residues T58,
V59, N60, I119, D122, R123 and K136.
3.1.2. Staurosporine binding to the ENT site. In this bind-
ing site, located at the entrance of the acetylcholine-binding
site, residues G169, E170, R171 (via p–cation interaction),
Q181, S388, K391, D393 and W400 bind the indolocarbazol
fragment of the molecule. In contrast, only residues Q181
and L183 interact with the other non-aromatic fragments of
the molecule.
3.1.3. Staurosporine binding to the EXC site. When this
allosteric modulator binds to this site, located at the extracel-
lular face of the receptor, its indolocarbazol moiety interacts
with residues T95, D99, Y166 (through p–p interactions),
L167 and V168. The non-indolocarbazol moiety interacts with
Table 1
Free energies of binding calculated for the allosteric modulators on
each allosteric site
Compound Free energy of binding (kcal/mol)
INC EXC ENT
Staurosporine 11.48 8.02 8.89
K252a 10.89 7.47 9.82
KT5720 11.75 9.67 8.42
KT5823 9.60 9.75 7.17
Go¨7874 10.87 8.48 –
Fig. 2. Most important orientations of staurosporine at the three
binding sites. Staurosporine is rendered as van der Waals spheres and
colored according to the binding site where it is located: EXC, red;
ENT, pink, INC, purple. Transmembrane helices are colored as
described in the caption of Fig. 1.
Fig. 1. Three-dimensional representation of the three allosteric sites
found with the aid of the program AutoDock. Each binding site is
rendered as a surface. The EXC (red) and ENT (pink) sites are
localized close to each other, at the surface of the extracellular face of
the receptor; the INC (purple) site is located at the opposite
(intracellular) face of the protein. Transmembrane helixes are colored
as follows: TM1, red; TM2, brown; TM3, olive; TM4, dark green;
TM5, light green; TM6, cyan; TM7, blue.
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and van der Waals interactions constitute the most important
forces driving the binding process.
3.2. K252a
This molecule docked on the three binding sites. The best
cluster, containing 56 out of 100 independent docking experi-
ments placed this allosteric modulator on the INC binding site,
while 10 out of 100 and 7 out of 100 docking runs placed it on
the ENT and the EXC binding sites (Fig. 3).3.2.1. K252a binding to the INC site. The residues that play
an important role in binding the indolocarbazol moiety of
k252a on the INC site are: T58, V59, N60, N61, D122, R123
(via p–cation interaction), S126, A135, R137, T354, F355
and N422. The non-indolocarbazol fragment interacts with
residues A224, T354, L357, V358 and E360.
3.2.2. K252a binding to the ENT site. When K252 binds to
the ENT site, the indolocarbazol is stabilized by interacting
with residues G169, R171 (via p–cation interaction), L174,
Q181, C391, K392, D393, V395 and W400. The non-indo-
locarbazol moiety makes contact with residues E170, Y252,
V256, S259 and W271.
3.2.3. K252a binding to the EXC site. In this binding site,
the indolocarbazol fragment interacts with residues G94,
T95, C98, D99, A160, I161, Y166 (through p–p interactions),
L167 and V16, while the rest of the molecule interacts with res-
idues F163, W164 and Q165.
3.3. KT5720
This allosteric modulator is the largest among the modula-
tors studied here. It contains a long aliphatic chain that can
easily interact with various aminoacids along the binding sites
Fig. 3. Relevant orientations of K252a at the three binding sites. The
modulator is rendered as van der Waals spheres and colored according
to the binding site where it is located: EXC, red; ENT, pink, INC,
purple. Transmembrane helices are colored as described in the caption
of Fig. 1.
Fig. 4. Most important orientations of KT5720 at the three binding
sites. KT5720 is rendered as van der Waals spheres and colored
according to the binding site where it is located: EXC, red; ENT, pink;
INC, purple. Transmembrane helices are colored as described in the
caption of Fig. 1.
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ranked cluster, containing 39 out of 100 independent runs,
placed KT5720 in the INC site; in contrast only 8 runs placed
it in the ENT binding site, and 13 placed it in the EXC one.
The best-ranked docking orientations on the three binding
sites are shown in Fig. 4.
3.3.1. KT5720 binding to the INC site. Residues T58, V59,
N60, D122, R123, S126, A135, F355 and N422 bind and sta-
bilize the indolocarbazol fragment, while residues F355,
S356, L357, V358 , K359 and E360 bind the non-aromatic
moiety of the compound.
3.3.2. KT5720 binding to the ENT site. KT5720 binds ver-
tically towards the entrance of the acetylcholine-binding site.
Residues R171 (p–cation interaction), Q181, K392, C394,
V395 and W400 (p–p interactions) are important in binding
the indolocarbazol moiety of this modulator at the ENT site.
Residues W91, V168, G169, E170, V173, L174, A175 and
G176 bind the non-indolocarbazol fragment of the molecule.
3.3.3. KT5720 binding to the EXC site. Residues T95, C98,
D99, A160, I161, Y166 (via p–p interactions), L167 and G169bind and stabilize the indolocarbazol fragment of this mole-
cule, while residues F163, W164, Q165, L183 and S184 interact
with the non-aromatic fragment of the molecule.
3.4. KT5823
AutoDock placed this ring-contracted analog of stauro-
sporine in the three binding sites described here. Thirty inde-
pendent runs out of hundred placed this modulator in the
INC site, while 10 out of 100 runs placed it in the EXC site;
in contrast, it was found that only a cluster containing six indi-
viduals docked the compound in the ENT site. Best-ranked
clusters are shown in Fig. 5.
3.4.1. KT5823 binding to the INC site. Residues N60,
R123, T354, F355, S356, V358, K359, E360 and N422 are
most important in binding the indolocarbazol fragment of
this molecule, while residues T58, V59, N60, S126, A135,
K136 and R137 interact with the non-aromatic fragment of
the molecule.
Fig. 5. KT5823 docking at the three allosteric sites. The structure of
the compound is rendered as van der Waals spheres and colored
according to the binding site where it is located: EXC, red; ENT, pink;
INC, purple. Transmembrane helices are colored as described in the
caption of Fig. 1.
Fig. 6. Three-dimensional representation of Go¨7874 binding at the
EXC (red) and INC (purple) allosteric sites. The allosteric modulator
is rendered as van der Waals spheres. Transmembrane helices are
colored as described in the caption of Fig. 1.
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the indolocarbazol moiety of KT5823 to this binding site are
R171 (via p–cation interaction), L174, Q181, F182, S388 and
D393. The rest of the molecule is bound and stabilized by res-
idues V168, G169, E170, Q181, Y381 and W400.
3.4.3. KT5823 binding to the EXC site. When KT5823
binds to this allosteric site, the aromatic indolocarbazol moiety
is mainly stabilized through p–p interactions with residue Y166,
and by hydrophobic/van der Waals interactions with residues
L167 and V168. On the other hand, the non-indolocarbazol
moiety interacts mostly through hydrophobic/van der Walls
interactions with W91, G94, T95, C98, A175 and G176.
3.5. Go¨7874
This allosteric modulator, a ring-opened analog of stauro-
sporine, lacks a common heterocycle, which is present in the
other molecules studied here. Interestingly, this molecule binds
only to two of the three possible binding sites. The best ranked
(and most populated) cluster, containing 40 out of 100 individ-
uals, placed Go¨7874 in the INC site, while only a cluster con-taining 10 individuals docked this molecule on the EXC
binding site. Best orientations found for Go¨7874 are presented
in Fig. 6.
3.5.1. Go¨7874 binding to the INC site. Residues that play
an important role in binding the aromatic moiety of this mol-
ecule are: T58, V59, N60, N61, D122, R123, S126 and E360.
The aliphatic moiety of Go¨7874 is bound by residues A224,
T354, F355, L357, V358 and E360, via hydrophobic/van der
Waals interactions.
3.5.2. Go¨7874 binding to the EXC site. The aromatic moi-
ety of this modulator is bound and stabilized mainly by p–p
interactions with residue Y166, and by hydrophobic and van
der Waals interactions with residues V168, G169 and L174.
The aliphatic fragment of the compound makes contact with
residues T95, C98, A160 (with the –NMe2 group), I161 and
L167. In the latter case, hydrophobic and van der Walls inter-
actions play a major role in the binding process.4. Discussion and conclusion
Previous studies have shown that the AutoDock program,
used for this analysis, is eﬃcient in ﬁnding unknown binding
sites on three-dimensional structures of proteins. The homol-
ogy model of the M1 muscarinic acetylcholine receptor has
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activity, mutagenesis and aﬃnity labeling data available for
this kind of receptors [18]. In addition, virtual screening of
binding sites on homology models based on the X-ray struc-
ture of rhodopsin, proved that this method is suitable in sev-
eral cases [19].
In this work, we combined the use of a rhodopsin-based
homology model of the M1 muscarinic acetylcholine receptor
and a well-known docking program. First, we performed a
short molecular dynamics to relax the structure. This proce-
dure allowed for a more accurate searching of the possible
binding sites by using docking simulations, so that the actual
binding sites could be eﬃciently targeted. Docking simulations
showed that in all cases, except for Go¨7874, there were three
diﬀerent allosteric sites where modulators preferentially
bound. Strikingly, those sites were located at both intra- and
extracellular faces of the receptor. The site labeled as ENT
was located at the entrance of the narrow gorge containing
the acetylcholine-binding site (extracellular face); residues
mentioned in Section 3 surrounded the site. These residues be-
long to transmembrane domains (TM) 6 and 7, and the extra-
cellular loop 3. This site was situated very close to the EXC
site, at the extracellular face of TM3 and TM4, and the extra-
cellular loop 2. The existence of both binding sites has been de-
scribed for the M2 muscarinic acetylcholine receptor [20].
Interestingly, the EXC binding site we describe here was also
found in the homology model of the M2 muscarinic acetylcho-
line receptor. In that case, Mohr and co-workers [20] modeled
the complex between diallylcaracurine V, N-methylscopol-
amine and the M2 muscarinic receptor. They found that the
binding site was located in a similar place as the binding site
described in the present study (in this case, the M1 subtype).
The most striking ﬁnding is the existence of a third allosteric
site, INC, located at the intracellular domain of the receptor.
This allosteric site is formed by a large number of aminoacids
that belong to TM2, TM3, TM7 and TM8, and the intracellu-
lar loop 3 (this loop connects TM5 and TM6 helices). Interest-
ingly, this site is located far from the agonist-binding site, but
very close to the domain where G proteins couple. In addition,
this INC site was ranked as number one in all docking simula-
tions, due to the greatest frequency of binding. This means that
it is the most preferred allosteric site among the three described
here. For example, the best-ranked cluster found for K252a
binding to the INC site contained 56 individuals, while only
7 individuals bound to the EXC site.
For the three allosteric sites, hydrophobic and van der Waals
forces play the most important role in binding and stabilizing
the modulator protein complexes. In addition, other kinds of
interactions seem to be important for the binding process.
For example, the ENT site contains an arginine (R171), which
binds the aromatic moiety of the compounds via p–cation
interactions; similarly, Y166 located at the EXC site, bind
the indolocarbazol moiety of the molecules through p–p inter-
actions.
In order to validate the model here presented, we performed
a docking simulation of gallamine on the receptor. We used the
same parameters as those set for the compounds studied here.
Interestingly, it was observed that gallamine preferentially
docked to the extracellular face of the receptor, linking sites
ENT and EXC. Mutagenesis studies have shown that the gal-
lamine-binding site appears to be a cleft that leads towards the
agonist/antagonist binding site [8]. This cleft contains severalresidues playing a major role in binding gallamine to the extra-
cellular face of the receptor. Among those residues, W400,
S388, D393 and E397, as well as the LAGQ sequence close
to W400, play a crucial role in binding gallamine to the recep-
tor [21–23]. Thus, the location of this binding site is in agree-
ment with our ﬁndings, particularly with the site labeled as
ENT. In addition, it should be remarked that extracellular sites
described here, ENT and EXC, might represent two possible
areas of attachment in the allosteric binding cleft instead of
two distinct binding sites, taking into consideration recent
studies carried out by Tranke et al. [24].
Experimentally, staurosporine inhibited the potency of gal-
lamine to bind to M1 receptors and modulated the ability of
KT5720 to inhibit N-methylscopolamine dissociation, but it
was not possible to determine whether staurosporine occluded
the binding of both gallamine and KT5720 or whether stauro-
sporine bound to the same site as K5720 and had negative
cooperativity with gallamine [8,9]. In contrast, KT5720 did
not aﬀect the potency of gallamine to inhibit N-methylscopol-
amine binding or dissociation from M1 receptors, suggesting
that gallamine, KT5720 and N-methylscopolamine could
simultaneously bind to the receptor. Furthermore, when
K75720 is bound to the receptor free receptor (as is our study),
there is neutral cooperativity between this allosteric agent and
gallamine [8,9]. In our study, we found that both staurosporine
and KT5720 were able to bind to both intra- and extracellular
faces of the receptor, suggesting that they can compete with
gallamine. However, recent modeling studies suggest that
KT5720 preferentially bind to the INC site, close to the intra-
cellular loop 3 (Espinoza-Fonseca and Trujillo-Ferrara,
unpublished work). This means that KT5720 can eﬀectively
bind to a diﬀerent site of that of gallamine, and at the same
time it can display allosteric properties. However, the complex
behavior of staurosporine still needs further work to be com-
pletely understood.
These facts, together with the studies performed with galla-
mine, suggest that the second allosteric site proposed by Bird-
sall and co-workers [9] is located in the intracellular face of the
receptor, very close to the intracellular loop 3.
As mentioned above, it is not diﬃcult to imagine that the
cooperation between EXC and ENT sites with the acetylcho-
line-binding site is due to local conformational changes that af-
fect the spatial distribution of the latter, and to suggest that the
mechanisms in which both EXC and ENT sites cooperate with
the agonist-binding site are probably not very complex. In con-
trast, the existence of a third binding site, INC, located far
from the agonist-binding site is not trivial. How do the ago-
nist-binding site and the INC site communicate? The existence
of a complex hydrogen bonding network might play an impor-
tant role in the communication process, and therefore in rein-
forcing the agonist binding to the receptor. This site is located
very close to the domain that couples G proteins, so it can pos-
itively cooperate with the agonist in order to reinforce the en-
ergy transfer along the transmembrane domain and destabilize
the ground state of the receptor. Therefore, there would be
greater coupling of the receptor to G proteins. An allosteric
site located close to the G protein-coupling domain could
either positively or negatively cooperate with the binding site.
This means that INC site could play an important role in
‘‘allowing’’ or ‘‘stopping’’ the energy ﬂow along the transmem-
brane domains of the receptor in a G protein-coupling-depen-
dent way. Thus, this allosteric site could work as an ‘‘energy
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receptor. It can be hypothesized that, in certain cases, ago-
nist-binding process could be replaced by allosteric activation.
In this particular case, G protein-coupling could be agonist-
binding independent, via the conformational re-arrangement
of the intracellular face of the receptor.
In summary, using a computational docking approach we
found the existence of multiple allosteric sites. According to
the docking results obtained here, ENT and EXC sites might
cooperate with the agonist-binding site by a standard mecha-
nism (induction of conformational changes on the agonist-
binding sites). In contrast, the INC site, here reported for
the ﬁrst time, might display a complex allosteric mechanism,
whether it is dependent or independent of the agonist binding
to the receptor.
It should be noted that staurosporine and staurosporine
derivatives are not ‘‘representative’’ for muscarinic allosteric
agents, because theses compounds are uncharged at physiolog-
ical pH whereas typical muscarinic allosteric agents posses at
least one quaternary, positively charged, nitrogen which helps
the molecule to be recognized by the aromatic residues at the
extracellular face of the receptor. However, staurosporine
derivatives are recognized using their aromatic moiety through
p–p and p–cation interactions. Thus, staurosporine-derived
compounds represent an attractive group of allosteric modula-
tors acting not only over the extracellular face of the receptor,
but also over its intracellular face, since they will be able to
cross the membrane towards the cytoplasm.
This study is limited only to the localization of the multiple
binding sites on the free receptor (e.g., no agonist or antagonist
is bound), and further experimental and computational studies
are needed to better understand how these allosteric sites coop-
erate, and by what mechanisms they reinforce or inhibit the li-
gand binding process. Such studies will also help to determine
whether or not the allosteric site INC could promote the G
protein binding in an agonist-independent manner. A better
understanding of these allosteric sites will be helpful for the de-
sign and discovery of speciﬁc and potent allosteric modulators
of the M1 muscarinic receptor, which could be clinically ap-
plied for the treatment of the Alzheimers disease.
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